Back to search

Article

The Clinical Kinase Index: Prioritizing Understudied Kinases as Targets for the Treatment of Cancer

2020-02-14

Abstract excerpt

The approval of the first kinase inhibitor, Gleevec, in 2001, ushered in a paradigm shift for oncological treatment—the use of genomic data for targeted, efficacious therapies. Since then, over 48 additional small molecule kinase inhibitors have been approved, solidifying the case for kinases as a highly druggable and attractive target class. Despite the established role deregulated kinase activity plays in cancer...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7cdb89f1-646b-5307-93b2-c3c5dafc6dda
DOI
10.1101/2020.02.14.943886
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The Clinical Kinase Index: Prioritizing Understudied Kinases as Targets for the Treatment of CancerDOI 10.1101/2020.02.14.943886
Select a neighboring publication to make it the new centre.